Curis stock has recently drawn increased attention following the latest round of analyst updates, with the consensus price target holding steady at $14.00 per share. While forecasts show little ...

The list of biotechs under clinical hold keeps getting longer. Curis is the latest company to join the list, with the FDA slapping a partial hold on a phase 1/2a leukemia study while it gathers ...

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Curis is back on investors’ radar after analysts reaffirmed a US$14.00 fair value per ...

CAMBRIDGE, Mass., Feb 12, 2010 (BUSINESS WIRE) -- Curis, Inc. (NASDAQ: CRIS), announced today that its licensee Debiopharm S.A. ("Debiopharm") has received approval from France's regulatory authority ...

The biotech's shares rode the wave of buyout speculation higher last month. Curis' shares were essentially trading sideways during the early part of the month, but they quickly came to life in the ...

LEXINGTON, Mass., Oct. 29, 2024 /PRNewswire/ -- Curis, Inc. ("Curis") (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule ...

- Genentech Also Determines not to Pursue Phase III Testing of GDC-0449 in Ovarian Cancer Indication - CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Curis, Inc. (NASDAQ: CRIS), a drug development company ...

Small-cap biotechnology firm Curis surged as much as 448% on Tuesday after the company released encouraging phase I data for its leukemia treatment, CA-4948. The company said it observed a Marrow ...

Curis goes down for the count after the Food and Drug Administration halts enrollment in an early-stage cancer study. Although we don't believe in timing the market or panicking over market movements, ...

What a difference a day makes. Following a serious pop for its stock on Wednesday, given very encouraging news about one of its pipeline drugs, Curis (NASDAQ: CRIS) saw its shares dive by almost 20% ...

LEXINGTON, Mass., July 2, 2025 /PRNewswire/ -- Curis, Inc. (CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, ...